Rifampicin and bioavailability in combination formulation

Authors

  • M SOSA Departamento de Tecnología Farmacéutica Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires
  • ME SZÉLIGA Departamento de Tecnología Farmacéutica Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires
  • A FERNÁNDEZ Departamento de Tecnología Farmacéutica Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires
  • C BREGNI Departamento de Tecnología Farmacéutica Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires

Keywords:

Rifampicin, Isoniazid, FDC products, Bioavailability, Stability, Polymorphism

Abstract

The drug rifampicin (R) is used as a first line antibiotic treatment for tuberculosis (TB), together withIsoniazide (H), Pyrazinamide (Z) and Ethambutol (E). According to recent statistics, there has been anincrease in TB on a worldwide scale, with the main causes being: monotherapies, the appearance ofresistant microorganisms, the lack of effective preventative programs, non-compliance to treatment andmistaken dosage schedules. The world health organisation (WHO) and the International Union AgainstTuberculosis and Lung Diseases(IUTALD) declared a state of emergency with respect to the disease andestablished programs to increase compliance to therapy and to reduce the incidence of problems arisingfrom such. Along these lines, a list of first line drug therapy treatments were established, whichincluded R, Z, H & E combinations at fixed dosage combinations (FDC), permitting safe combinedadministrations of the drugs at correct dosage levels. These fixed dose combinations have been officiallyrecommended by the WHO in the treatment of TB. However, as has been widely recognised in numerousscientific publications, in such formulations, there are factors that alter the bioavailability of R. Theobjective of this work has been to study the most relevant aspects concerning R bioavailability alterationsand to consider possible solutions to the problem.

Downloads

Download data is not yet available.

References

World Health Organization. Report on infectious diseases. Removing obstacles to healthy development. World Health

Organization Document 1999;WHO/CDC/99.1:1-68.

Goodman y Gilman; Las Bases Farmacológicas de la Terapéutica, Novena edición, 1996, Mc Graw-Hill. Interamericana, México; cap.48: 1225

Singh S., Mariappan T.T., Snakar R., Sarda N., Sing B., A Critical review of the probable reasons for the poor/variable bioavailability of rifampicina from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem; Int. J. Pharm 2001, 228: 5-17

Gallo G.G, Radaelli P, 1976 Rifampicin In: Florey K (Ed.), Analytical Profiles of Drug Substances, Academic Press, London, pp: 468-513

Connors K.A., Amidon G.L.; Stella V.J., Chemical Stability of Pharmaeuticals. Second Edition, p: 728-732

Sing S., Mariappan T.T., Sharda N., Kumar S., Chakraborti A.K., The Reason for an Increase in Decomposition of Rifampicin in the Presence of Isoniazid under Acid Conditions, Pharm. Pharmacol. Commun. 2000, 6: 405-410

Sing S., Mariappan T.T., Sharda N., Singh B., Degradation of Rifampicin, Isoniazid and Pyrazinamide from Prepared Mixtures and Marketed Single and Combination Products Under Acid Conditions, Pharm. Pharmacol. Commun. 2000, 6: 491-494.

Shishoo C. J., Shan S.A., Rathod I.S., Savale S.S., Vora M.J.; Impared Bioavailability of rifampicina in presence of isoniazida from fixed dose combination (FDC) formulation. Int. J. Pharm 2001, 228: 53-67

Pelizza G., Nebuloni M., Ferrari P., Gallo G.G, Polymorphism of Rifampicin; Il Fármaco 1977, 32:471-481

Henwoood S.Q., Liebenberg W., Tiedt L.R., Lötter A.P, Villiers M.M; Characterization of the Solubility and Dissolution Properties of Several New Rifampicin Polymorphs, Solvates and Hydrates; Drug Dev. Ind. Pharm. 2001, 27(10):1017-30

Agrawal S., Ashokraj Y., Bharatam P.V., Pillai O., Panchangnula R.; Solid-state characterization of rifampicina samples and its biopharmaceutic relevance; European J. Pharm. Sci 2004, 22: 127-144

Goodman y Gilman; Las Bases Farmacológicas de la Terapéutica, Novena edición, 1996, Mc Graw-Hill. Interamericana, México; cap.48: 1230

M. H.Beers, M.D. y R. Berkow, M.D. El Manual Merk. Décima edición, 1999, Harcourt, España, cap.304: 2615.

L.R.Lépori P.R. Vademécum Décima edición, 2003, E.C.S.A. Buenos Aires, Sección III Índice de interacciones medicamentosas: 401.

Khalil S.A.H., El-Khordagui L.K., El-Gholmy Z.A., Effect of antacids on oral absorption of rifampicina; Int. J. Pharm. 1984, 20:99-106

Mariappan T.T., Singh S., Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat; Int. J. Tuberc. Lung Dis. 2003, 7(8):797-803.

Downloads

Published

2005-09-20

How to Cite

1.
SOSA M, SZÉLIGA M, FERNÁNDEZ A, BREGNI C. Rifampicin and bioavailability in combination formulation. Ars Pharm [Internet]. 2005 Sep. 20 [cited 2024 Jul. 22];46(4):353-64. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/5091

Issue

Vol. 46 No. 4 (2005)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).